witnessing the start of a 5 to Disallowed., page-271

Hi Aces,

Thanks for your reply and more respect to you.

I've been following the TDD space for some time now and have gained further interest for understanding the mechanisms of internalization through intracellular trafficking of oligonucleotides or rather drug delivery of siRNA and antisense oligonucleotides via VR-1 vanilliod receptors used as the primary and afferent nociceptor functions...

"There is great potential for antisense and siRNA oligonucleotides to become mainstream therapeutic entities thanks to their high specificity and wide therapeutic target space compared with small molecules. Despite this potential, the pharmacological targets within the cells are less accessible to oligonucleotides that are hydrophilic and often charged. Oligonucleotides access their intracellular targets mainly by means of endocytosis, but only a fraction of them reach their targets, as delivery requires functional synergy of cellular uptake and intracellular trafficking."

A GSK tie-in for ANP would certainly be a game changer imo as GSK are progressing on many fronts with RNA therapy including a Santaris Pharma alliance for microRNA technology and Prosensa's antisense discovery which commenced phaseIII trials at the beginning of this year for DMD. This study has also been designated orphan drug status.

"Santaris Pharma has LNA technology, a 3rd generation antisense chemistry used to develop new classes of RNA medicines, called RNA Antagonists and microRNA antagonists. Santaris Pharmas microRNA Antagonists are targeted against tissue specific microRNAs associated with cancer and metabolic disorders."

Both Regulus and Alnylam which I believe are connected to Isis have existing alliance programs underway with GSK so I guess we could consider a six degrees of seperation puts a good speculative possiblity towards collaborating with ANP.

From an objective point of view Glaxo have restructured their business model to cut their excessive R&D spend and as a result many of their new collaborating partnerships are established during the later stages of drug development. Imo, ANP will probably be required to complete phaseII studies before attracting the big boys to the party. If you believe that the directors have already been in discussions with GSK I would be interested in learning more as they do have what's known as the Centre of Excellence for Drug discovery (CEDD) which was established for risk-sharing partnerships during early stage development. Still a great vote of confidence for any company to make it on the GSK team.

"CEDD focuses on building an innovative pipeline through both internal efforts and external alliances with other companies and research institutions and will focus on 'virtualising' a portion of the inflammatory diseases pipeline by forming multiple risk-sharing/reward-sharing alliances." - GSK/Regulus Alliance

I believe GSK will become a clear leader in the health industry which will also integrate the long overdue paradigm shift towards a safer fast moving consumer health goods industry, much as Apple have long become the clear leaders for being what's defined as Disruptive Technology Innovators... It won't be long before the iPhone becomes an integral part of the healthcare landscape... sounds scary but they already have one foot in the door whilst the sleeping competitor is still struggling just to copy the packaging.
___

Hi 64eheh,

"abdm.....I think you will find that it is not ANP that has changed,but the overall market.If you follow some of the market analysis carried out on the XJO forum,you will discover that sentiment is slowly returning to the overall market"

With all due respect I find the XJO thread to be a bit of a bears club... "sentiment slowly returning" with emphasis on "slowly" providing the correct metaphor.

I earned some bragging rights back on October 4 with this DJPIN post - not only picking the bottom but also spot on with closing points for the Dow whilst most of the XJO experts continued calling a crash for the next 4 weeks. (maybe a little arrogant of me but I could't help myself - sorry ;)

The XJO thread is home to the best chartest on HC - I certainly appreciate that and do respect the invaluable contributions to that thread but imo much has changed since the GFC which I believe most effected the psychology behind the markets. In many cases with speculative stocks technical analysis is no longer applicable with the exception of perhaps where the Acc/Dis chart for its accuracy might show an underlying positive/negative divergence but imo a good investor today would be wiser to rely more on other available resources

I don't discount using technical analysis as tool in the decision making process but I can't rely on it for its accuracy in making predictions but rather more for its inaccuracy or tardiness for better word ;)

If I want to go sailing tomorrow, last weeks weather forecast is of little use to me because I always go long.